EMERGE (Study 302)
E133123
UNEXPLORED
EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.